**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 70830

**Manuscript Type:** ORIGINAL ARTICLE

***Case Control Study***

**Methylprednisolone accelerate chest computed tomography absorption in COVID-19: A three-centered retrospective case control study from China**

Lin L *et al*. Retrospective case control study

Lan Lin, Dan Xue, Jin-Hua Chen, Qiong-Ying Wei, Zheng-Hui Huang

**Lan Lin, Dan Xue, Qiong-Ying Wei, Zheng-Hui Huang,** Department of Respiratory Medicine, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China

**Jin-Hua Chen,** Department of Medical Administration, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China

**Author contributions:** Lin L and Huang ZH designed the study and drafted the manuscript; Lin L, Xue D, Wei QY and Huang ZH were responsible for the clinical treatment of patients and conducted the acquisition of clinical data; Chen JH conducted the acquisition, analysis and interpretation of data; Chen JH and Huang ZH revised the manuscript for relevant important intellectual content; All authors have read and approved the final version of the manuscript.

**Supported by** the Fujian Medical University COVID-19 Prevention and Treatment Research Contingency Key Project, No. 2020YJ006; the Science and Technology Program Guided Projects, Fujian Province, China, No. 2020Y0036.

**Corresponding author: Zhenghui Huang, MD, Associate Chief Physician,** Department of Respiratory Medicine, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Gulou District, Fuzhou 350001, Fujian Province, China. 13665028181@163.com

**Received:** August 17, 2021

**Revised:** November 12, 2021

**Accepted:** December 2, 2021

**Published online:** January 14, 2022

**Abstract**

BACKGROUND

Based on the results of some large randomized controlled trials (RCTs) confirmed the efficacy of corticosteroids in coronavirus disease 2019 (COVID-19), corticosteroids have been included in World Health Organization guidelines, but remain controversial.

AIM

To investigate the efﬁcacy and safety of low-to-moderate dose (30 to 40 mg/d) short-term methylprednisolone for COVID-19 patients.

METHODS

The clinical data of 70 patients diagnosed with COVID-19 who received antiviral therapy with Arbidol for 7-10 d before admission but had no obvious absorption on chest computed tomography (CT) imaging were retrospectively analyzed. Arbidol (as the control group) and methylprednisolone (as the corticosteroid group) were given respectively after admission. After treatment, chest CT was reexamined to evaluate the absorption of pulmonary lesions. Additionally, we evaluated and compared the lymphocyte count, erythrocyte sedimentation rate (ESR), interleukin-6(IL-6), serum ferritin, lactate dehydrogenase (LDH), creatine kinase-MB (CK-MB), hypersensitive C-reactive protein (hs-CRP) and D-dimer levels, and also analyzed the incidence of toxic and side effects.

RESULTS

All patients in the corticosteroid group had varying degrees of CT absorption, which was significantly better than that in the control group (CT obvious absorption rate: 89.47% *vs* 12.5%, *P* < 0.05). The average daily dose and course of methylprednisolone in the patients with significant improvement on chest CT was (38.55 ± 13.17) mg and (6.44 ± 1.86) d respectively. During the treatment, the lymphocyte count, ESR, IL-6, serum ferritin, LDH, CK-MB, hs-CRP and D-dimer levels all improved gradually, indicating that both Arbidol and methylprednisolone therapy were contributed to improving the condition of COVID-19 patients. The corticosteroid regimen did not prolong the clearance time of SARS-CoV-2. There were no severe adverse reactions such as gastrointestinal bleeding, secondary severe infection, hypertension, diabetic ketoacidosis, mental disorders or electrolyte disorders during the whole corticosteroid treatment process.

CONCLUSION

Low-to-moderate dose short-term methylprednisolone can accelerate the chest CT imaging absorption of COVID-19 so as to improve symptoms and alleviate the condition in a short term, reduce the hospital stay, meanwhile avoid severe COVID-19 phases. The protocol has been proven to be effective and safe in clinical use.

**Key Words:** COVID-19; Corticosteroid; Methylprednisolone; Treatment

**©The Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Lin L, Xue D, Chen JH, Wei QY, Huang ZH. Methylprednisolone accelerate chest computed tomography absorption in COVID-19: A three-centered retrospective case control study from China. *World J Clin Cases* 2022; 10(2): 426-436

URL: <https://www.wjgnet.com/2307-8960/full/v10/i2/426.htm>

DOI: https://dx.doi.org/10.12998/wjcc.v10.i2.426

**Core Tip:** This study aimed to explore the efficacy and safety of methylprednisolone for treating coronavirus disease 2019 (COVID-19). Low-to-moderate dose short-term methylprednisolone could accelerate the chest computed tomography imaging absorption of COVID-19 and prevent it from deteriorating into critical type, shorten hospital stay and save medical resources.

**INTRODUCTION**

As an emerging severe infectious respiratory disease, coronavirus disease 2019 (COVID-19) has caused a pandemic outbreak with a high infection rate, high mortality and general population susceptibility, which makes this disease a major threat to international health and economy[1]. In the absence of specific treatment methods and widespread mass vaccination, it is urgent to find clinically effective drugs to reduce mortality and shorter hospitalization stay. The therapeutic effect of corticosteroids in severe acute respiratory syndrome (SARS) has been confirmed before[2,3], but the use of corticosteroids in COVID-19 remains controversial due to the absence of evidence from randomized controlled trials(RCTs)[4]. Clinically, we observed that some patients who received low-to-moderate dose short-term corticosteroids had better pulmonary imaging absorption. A retrospective analysis of clinical data was conducted to explore the optimal time, dosage, and course of corticosteroids in the treatment of COVID-19, expecting to evaluate the efficacy and safety profiles of corticosteroid therapy.

**MATERIALS AND METHODS**

***Subjects***

A total of 70 hospitalized patients who were admitted to Wuhan Union Hospital, Renmin Hospital of Wuhan University Hubei General Hospital and Wuhan Jinyintan Hospital from January 27, 2020, to March 30, 2020 were included in this study. The inclusion criteria were as follows: ① the patients had confirmed COVID-19 and typical radiological characteristics; and ② the patients were treated with Arbidol Hydrochloride Tablets (hereinafter, Arbidol) for 7-10 d before admission, and no obvious absorption was found on reexamination of chest computed tomography (CT) scan. The exclusion criteria were as follows: ① previous rheumatic immune system related diseases and long-term use of corticosteroids; ② use of corticosteroids within 2 mo before admission; ③ serious cardiovascular and cerebrovascular diseases, refractory hypertension, epilepsy or delirium, glaucoma; ④ active gastrointestinal bleeding in the recent 3 mo; ⑤ combination with bacterial infection; ⑥ mild and critical types or ⑦ patients received antiviral therapy other than Arbidol before admission. We collected the clinical data of patients, including sex, age, underlying diseases, clinical symptoms, epidemiological history, radiological characteristics, laboratory tests, *etc*. The diagnostic criteria and clinical classification referred to the Diagnosis and Treatment Protocol for COVID-19 (Trial version 7th)[5]. The study was retrospectively analyzed and approved by the Medical Ethics Committee of Fujian Medical University Union Hospital (ethics approval No. 2020KJTXGF001) and conformed to the principles of the Declaration of Helsinki.

***Therapy and groups***

All patients were received routine oxygen therapy and nutritional support. Some of them continued to be treated with Arbidol (200 mg tid) as the control group, and some were treated with methylprednisolone (orally or intravenously) as the corticosteroid group. Chest CT was reexamined to evaluate the absorption of pulmonary lesions after 7-10 d therapy. Two senior radiologists evaluated the chest radiological characteristics independently and contributed to confirming the degree of absorption, which was classified as four situations: no absorption, slightly absorption, obvious absorption and progression.

***Efficacy evaluation***

Routine blood tests, liver and kidney function tests, hypersensitive C-reactive protein (hs-CRP) levels, erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6), serum ferritin (SF), lactate dehydrogenase (LDH), creatine kinase-MB (CK-MB), and D-dimer levels were evaluated before and after treatment. Throat swab samples were collected for detecting SARS-CoV-2 RNA by real-time reverse transcription polymerase chain reaction (RT-PCR). During the treatment, the patient's temperature, respiration, pulse rate, blood pressure, blood glucose and oxygen saturation were closely monitored. The discharge criteria were as follows: body temperature that returned to normal for more than 3 d; respiratory symptoms that improved significantly; chest CT that showed significant improvement of acute exudative lesions; and two consecutive negative nucleic acid tests of respiratory tract specimens (sampling interval of at least 24 h).

***Statistical analysis***

Statistical analysis was performed using SPSS software (version 17.0). Enumeration data are represented by the number of cases and percentages. In addition, the differences in the variables between the corticosteroid group and control group were evaluated using the chi-square test or Fisher’s exact test for categorical variables. Ridit analysis was used for ranked data. Normally distributed measurement data are represented as the mean ± SD, and comparisons between groups were performed by the T-test or two-factor repeated measurement analysis of variance. Nonnormally distributed data are represented by the median and mean rank, and comparisons between groups were performed by the rank-sum test. The index differences before initial medication, post initial medication and post-subsequent medication between the corticosteroid group and control group were compared by repeated-measures analysis. Spearman's correlation coefficient was used to determine the association between blood glucose variation and diabetes. *P*<0.05 was considered to indicate a statistically significant difference.

**RESULTS**

***General Characteristics of the Patients***

All 70 patients were local cases in Wuhan. The general characteristics of the patients are shown in Tables 1 and 2. There were 32 patients in the control group aged from 33 to 85 years old among whom 14 patients had underlying diseases (8 cases with of hypertension, 4 cases of type 2 diabetes, 2 cases of chronic obstructive pulmonary disease, 1 case of hyperlipidemia, 2 cases of gallstone, 1 case of kidney stone, 1 case of Parkinson's disease, 1 case of rheumatoid arthritis and 1 case of systemic lupus erythematosus). There were 38 patients in the corticosteroid group aged from 27-91 years old among whom 15 patients had underlying diseases (8 cases of hypertension, 7 cases of type 2 diabetes, 1 case of rheumatoid arthritis, and 1 case of postoperative cervical cancer). There was no significant difference between the two groups in the gender distribution, classification, clinical symptoms or baseline data of underlying diseases (*P* > 0.05) (Tables 1-2). There was no significant difference between the two groups in the time of medication (*P* > 0.05) (Table 2). Since the time of admission did not conform to the normal distribution, the rank-sum test obtained Z = -0.132 and *P* = 0.898, suggesting that the days from the onset of illness to admission between the two groups was not statistically significant.

***Use of methylprednisolone***

The total days of methylprednisolone use in the corticosteroid group were 2-12 d, with the initial dose ranging from 24 to 80 mg. The patients in corticosteroid group were divided into the non-obvious absorption group (including no absorption, slightly absorption and progression) and obvious absorption group according to whether chest CT was obviously absorbed after medication. There was no significant difference in the course of corticosteroid therapy, total or daily corticosteroid dosage between the two groups (*P* > 0.05) (Table 3).

***Therapeutic******effect******evaluation***

During the treatment, the viral nucleic acid condition of the throat swab was dynamically monitored. If two consecutive nucleic acid tests of throat swab specimens (sampling interval of at least 24 h) were negative, the time of the first test turned negative was taken as the negative nucleic acid conversion time, and the time interval from the onset date to the negative nucleic acid conversion time was taken as the nucleic acid clearance time. The negative conversion rates of SARS-CoV-2 nucleic acid were 65.62% in the control group and 73.68% in the corticosteroid group before medication. The negative conversion rates of SARS-CoV-2 nucleic acid in the control group and the corticosteroid group were 93.75% and 97.37% after medication, respectively. There was no significant difference between the two groups in the negative conversion rate (*P* > 0.05) (Table 4) and total clearance time of SARS-CoV-2 nucleic acid (*P* > 0.05) (Table 5). After medication, all the patients in the corticosteroid group had varying degrees of CT absorption, with an obvious CT absorption rate of 89.47%. In contrast, 40.63% patients in the control group showed no absorption in chest CT and the CT obvious absorption rate was only 12.5%. The CT absorption degree of the corticosteroid group was significantly better than that of the control group, with a statistically significant difference (*P* < 0.05) (Table 4). None of them developed into critical type.

All the 70 patients completed the detection of peripheral blood indicators before and after medication. The results were as follows (Tables 6-9): ① There was no significant difference in the lymphocyte count, ESR, SF, hs-CRP and IL-6 Level between the two groups. However, for the patients in the same group, the values of the above indexes varied at different time points with statistical significance (lymphocyte count: before the medication < after the medication; ESR, SF, hs-CRP and IL-6 Level: before the medication > after the medication). However, the interaction effects between the groups and time points did not exhibit significant differences. In other words, there was no significant difference in the gradient of each index. ② The LDH, CK-MB and D-dimer values of the two groups were significantly different (the corticosteroid group>the control group). Moreover, for the patients in the same group, the values of the above indexes varied at different time points with statistical significance (LDH, CK-MB and D-dimer levels: before the medication > after the medication). However, the interaction effects between the groups and time points also exhibited no significant differences.

***Observation of adverse reactions to corticosteroid therapy***

We observed no severe adverse reactions such as gastrointestinal bleeding, secondary severe infection, hypertension, diabetic ketoacidosis, mental disorders or electrolyte disorders during the whole corticosteroid treatment process (Table 10). There were 11 cases (28.95%) of hyperglycemia in the corticosteroid group, among which only 2 patients needed short-acting insulin hypodermic injections to control blood glucose, while no elevated blood glucose was observed among patients in the control group. The Chi-square test was used to compare the incidence of elevated blood glucose between the two groups (*c*2 = 10.990, 28.95% *vs* 0%, *P* = 0.001). Spearman rank correlation analysis showed no significant correlation between elevated blood glucose and the existence of underlying diabetic diseases (*r* = 0.052, *P* = 0.668).

**DISCUSSION**

COVID-19 is an emerging respiratory infectious disease caused by the novel SARS-CoV-2 that has declared a pandemic outbreaks. SARS-CoV-2 including new variants is characterized by strong infectivity, diverse transmission routes, and non-specific clinical manifestations, and people are generally susceptible. Currently, the treatment for COVID-19 is still mainly focused on antivirals, nutritional support, respiratory support, expectorants, antiasthmatics and immune enhancement. Unfortunately, there is no specific drug to treat COVID-19[1,4-5].Therefore, searching for effective treatment for COVID-19 has attracted considerable attention worldwide.

Corticosteroids offer advantages over conventional therapy for alleviating clinical symptoms, reducing mortality and improving prognosis by inhibiting excessive inflammatory responses and cytokine release and reducing systemic toxic symptoms and pulmonary exudation[6].Clinical trials of dexamethasone have shown that it decrease 28-d mortality in patients with COVID-19 receiving respiratory support, but has no benefit in patients not require oxygen even may be harmful[7].A randomized clinical trial concluded that use of intravenous dexamethasone increased the number of ventilator free days over a 28-d in patients with COVID-19 and moderate or severe acute respiratory distress syndrome (ARDS)[8]. Wu *et al*[9] reported that in patients with ARDS due to COVID-19, a standard dose of methylprednisolone significantly reduced the risk of death by 62%.

However, corticosteroids are a "double-edged sword". On the one hand, these drugs can help reduce excessive inflammatory responses; on the other hand, they may suppress immune function and delay the clearance of SARS-CoV-2 RNA[5,10]. Whether patients with COVID-19 benefit from adjunctive corticosteroids still a debated issue. It has been reported that corticosteroids did not reduce mortality in patients with severe COVID-19 in intensive care units (ICUs)[11]. Liu *et al*[12] carried out their study among 137 participants with 2019-nCOV infection found no significant benefits from systemic corticosteroid therapy. Evidence even showed that mortality benefit in severely ill COVID-19 patients treated with corticosteroids from a meta-analysis of 21,350 COVID-19 patients[13]. In view of this, to make good use of the "double-edged sword" of corticosteroids to maximize the therapeutic effect while minimizing adverse effects, the timing, dosage and treatment course are of vital importance and should be carefully considered by clinicians. Few studies focused on the effects of corticosteroids on pulmonary imaging absorption in patients with COVID-19, so this study highlights this issue.

Arbidol is a non-nucleoside broad-spectrum antiviral drugthat has been proven to be effective against coronavirus in vitro[14,15]. A retrospective study of 69 COVID-19 patients revealed that Arbidol treatment improved the discharge rate (33% in the -treated group *vs* 19% in the -untreated group) and decreased the mortality rate[16].Arbidol treatment has been recommended as antiviral therapy according to the 7th trial version of Diagnosis and Treatment Protocol for COVID-19 released by the China’s National Health Commission: for adults, a dose of 200 mg tid for no more than 10 d is recommended[5].

In this study, a total of 70 patients with no obvious absorption on chest CT after 7-10 d of Arbidol antiviral therapy were included in strict accordance with the recommended treatment regimen. Arbidol (as the control group) and methylprednisolone (as the corticosteroid group) were given respectively after admission. There was no difference between the two groups in the time of medication (*P* > 0.05). All patients in the corticosteroid group had varying degrees of CT absorption, and the CT absorption degree in the corticosteroid group was significantly better than that in the control group (CT obvious absorption rate: 89.47% *vs* 12.5%, *P* < 0.05). In the corticosteroid group, there was no significant difference in the course of treatment, total dosage and daily corticosteroid dosage between the patients with obvious CT absorption and those without obvious CT absorption (*P* > 0.05), indicating that there was no difference in the corticosteroid dosage and medication time between 34 patients with obvious CT absorption and 4 patients with slight absorption.

The average daily methylprednisolone dose of the 34 patients with significant improvement in chest CT was (38.55 ± 13.17) mg, and the average course of methylprednisolone use was (6.44 ± 1.86) d; thus, this could be regarded as a low-to-moderate dose short-term regimen. There was no significant difference in the negative conversion rate and total clearance time of SARS-CoV-2 nucleic acid between the corticosteroid group and the control group (*P* > 0.05), indicating that the corticosteroid regimen did not affect the clearance time of the virus.

Lymphopenia and elevated levels of LDH, hs-CRP, D-dimer, IL-6, CK-MB, ESR and SF can be regarded as risk factors for progression or predictors of disease severity of COVID-19[9,16-23]. During the treatment, lymphocytes gradually increased and the ESR, SF, LDH, CK-MB, hs-CRP, IL-6 and D-dimer levels gradually decreased. It was suggested that both Arbidol and corticosteroids therapy can improve COVID-19 patients' condition.

In the whole treatment process of this study, we did not observe serious adverse reactions such as gastrointestinal bleeding, secondary severe infections, hypertension, diabetic ketoacidosis, mental disorders and electrolyte disorders. There were 11 cases (28.95%) of hyperglycemia in the corticosteroid group, which was statistically significant compared with the control group (0%) (*P* = 0.001). Spearman rank correlation analysis suggested that there was no correlation between elevated blood glucose and the existence of underlying diabetic diseases, indicating that the increase in blood glucose was caused by corticosteroids. However, only 18.18% (2/11) of patients with hyperglycemia needed short-acting insulin to control blood glucose. Thus, the above corticosteroid regimen was safe. During the treatment of COVID-19 with corticosteroids, we should monitor the patients' blood glucose more closely to avoid the occurrence of life-threatening situations such as hyperosmotic hyperglycemia coma and ketoacidosis.

**CONCLUSION**

Our study showed that the chest CT absorption in the corticosteroid group was significantly better than that in the control group. Low-to-moderate dose short-term methylprednisolone treatment can promote pulmonary radiological absorption and improve the indexes of lymphocyte count, ESR, SF, LDH, CK-MB, hs-CRP, IL-6 and D-dimer levels. The corticosteroid regimen was not associated with any serious adverse reactions and did not delay the clearance time of SARS-COV-2. COVID-19 has caused a lot of morbidity and mortality worldwide, occupying more medical resources. Low-to-moderate dose short-term methylprednisolone can rapidly improve symptoms, oxygenation and pulmonary function, alleviate the patients’ condition in a short term, reduce the hospital stay, avoid severe COVID-19 phases and save medical resources ultimately. Therefore, we suggest that confirmed COVID-19 patients with the common and severe types with no obvious improvement on chest CT after initial antiviral treatment with Arbidol can be treated with a low-to-moderate dose (30 to 40 mg/d) and short-term treatment (5-7 d) of methylprednisolone. A personalized regimen should be developed based on the underlying disease and infectious severity of the patient to fully demonstrate the advantages of corticosteroids in clinical use and to avoid adverse effects. Furthermore, RCTs need to be designed to further confirm the therapeutic effect of corticosteroids in the future.

**ARTICLE HIGHLIGHTS**

***Research background***

Coronavirus disease 2019 (COVID-19) has caused a pandemic outbreak with a high infection rate, high morbidity and mortality, occupying more public medical resources. Therefore, it is urgent to find effective treatment for COVID-19.

***Research motivation***

The use of corticosteroids in COVID-19 has been included in World Health Organization guidelines, but still remains controversial.

***Research objectives***

Examine the efﬁcacy and safety of low-to-moderate dose short-term methylprednisolone on COVID-19 patients.

***Research methods***

Seventy COVID-19 patients received antiviral therapy with Arbidol for 7-10 d before admission but had no obvious absorption on chest computed tomography (CT) imaging were retrospectively analyzed. Arbidol (as the control group) and methylprednisolone (as the corticosteroid group) were given respectively after admission. After treatment, chest CT was reexamined to evaluate the absorption of pulmonary lesions.

***Research results***

The degree of CT absorption in the corticosteroid group was significantly better than that of control group (*P* < 0.05). The average daily dose and course of methylprednisolone in the patients with significant improvement on chest CT was (38.55 ± 13.17) mg and (6.44 ± 1.86) d respectively.

***Research conclusions***

Low-to-moderate dose short-term methylprednisolone can accelerate the chest CT imaging absorption of COVID-19.

***Research perspectives***

The protocol has been proven to be effective and safe in clinical use, it can improve the condition, reduce the hospital stay, avoid severe phases and save medical resources.

**ACKNOWLEDGEMENTS**

We would like to express our heartfelt thanks to all the medical staff at Wuhan Union Hospital, Renmin Hospital of Wuhan University Hubei General Hospital and Wuhan Jinyintan Hospital.

**REFERENCES**

1 **Wang C**, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet* 2020; **395**: 470-473 [PMID: 31986257 DOI: 10.1016/S0140-6736(20)30185-9]

2 **Zhao Z**, Zhang F, Xu M, Huang K, Zhong W, Cai W, Yin Z, Huang S, Deng Z, Wei M, Xiong J, Hawkey PM. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. *J Med Microbiol* 2003; **52**: 715-720 [PMID: 12867568 DOI: 10.1099/jmm.0.05320-0]

3 **Chen RC**, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, Zhong N. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. *Chest* 2006; **129**: 1441-1452 [PMID: 16778260 DOI: 10.1378/chest.129.6.1441]

4 Guide for the prevention and treatment of coronavirus disease 2019. *Zhonghua Jiehe He Huxi Zazhi* 2020; **43**: 473-489 [DOI: 10.3760/cma.j.cn112147-112147-20200321-00392]

5 New coronavirus pneumonia prevention and control program (7nd ed.) (in Chinese). 4 March 2020. National Health Commission of the People's Republic of China. Available from http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf

6 **Jiang S**, Liu T, Hu Y, Li R, Di X, Jin X, Wang Y, Wang K. Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: A meta-analysis. *Medicine (Baltimore)* 2019; **98**: e16239 [PMID: 31261585 DOI: 10.1097/MD.0000000000016239]

7 **RECOVERY Collaborative Group.**, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med* 2021; **384**: 693-704 [PMID: 32678530 DOI: 10.1056/NEJMoa2021436]

8 **Tomazini BM**, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, Avezum A, Lopes RD, Bueno FR, Silva MVAO, Baldassare FP, Costa ELV, Moura RAB, Honorato MO, Costa AN, Damiani LP, Lisboa T, Kawano-Dourado L, Zampieri FG, Olivato GB, Righy C, Amendola CP, Roepke RML, Freitas DHM, Forte DN, Freitas FGR, Fernandes CCF, Melro LMG, Junior GFS, Morais DC, Zung S, Machado FR, Azevedo LCP; COALITION COVID-19 Brazil III Investigators. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. *JAMA* 2020; **324**: 1307-1316 [PMID: 32876695 DOI: 10.1001/jama.2020.17021]

9 **Wu C**, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020; **180**: 934-943 [PMID: 32167524 DOI: 10.1001/jamainternmed.2020.0994]

10 **Ling Y**, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, Wu F, Song ZG, Huang W, Chen J, Hu BJ, Wang S, Mao EQ, Zhu L, Zhang WH, Lu HZ. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. *Chin Med J (Engl)* 2020; **133**: 1039-1043 [PMID: 32118639 DOI: 10.1097/CM9.0000000000000774]

11 **Zhou W**, Liu Y, Tian D, Wang C, Wang S, Cheng J, Hu M, Fang M, Gao Y. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. *Signal Transduct Target Ther* 2020; **5**: 18 [PMID: 32296012 DOI: 10.1038/s41392-020-0127-9]

12 **Liu K**, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, Li CH, Li GC, Liu HG. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J (Engl)* 2020; **133**: 1025-1031 [PMID: 32044814 DOI: 10.1097/CM9.0000000000000744]

13 **Cano EJ**, Fonseca Fuentes X, Corsini Campioli C, O'Horo JC, Abu Saleh O, Odeyemi Y, Yadav H, Temesgen Z. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. *Chest* 2021; **159**: 1019-1040 [PMID: 33129791 DOI: 10.1016/j.chest.2020.10.054]

14 **Hulseberg CE**, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA, Shoemaker CJ, Schmaljohn CS, Polyak SJ, White JM. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses. *J Virol* 2019; **93** [PMID: 30700611 DOI: 10.1128/JVI.02185-18]

15 **Khamitov RA**, Loginova SIa, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. *Vopr Virusol* 2008; **53**: 9-13 [PMID: 18756809]

16 **Wang Z**, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. *Clin Infect Dis* 2020; **71**: 769-777 [PMID: 32176772 DOI: 10.1093/cid/ciaa272]

17 **Xu PP**, Tian RH, Luo S, Zu ZY, Fan B, Wang XM, Xu K, Wang JT, Zhu J, Shi JC, Chen F, Wan B, Yan ZH, Wang RP, Chen W, Fan WH, Zhang C, Lu MJ, Sun ZY, Zhou CS, Zhang LN, Xia F, Qi L, Zhang W, Zhong J, Liu XX, Zhang QR, Lu GM, Zhang LJ. Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study. *Theranostics* 2020; **10**: 6372-6383 [PMID: 32483458 DOI: 10.7150/thno.46833]

18 **Zhou F**, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054-1062 [PMID: 32171076 DOI: 10.1016/S0140-6736(20)30566-3]

19 **Li K**, Chen D, Chen S, Feng Y, Chang C, Wang Z, Wang N, Zhen G. Predictors of fatality including radiographic findings in adults with COVID-19. *Respir Res* 2020; **21**: 146 [PMID: 32527255 DOI: 10.1186/s12931-020-01411-2]

20 **Jang JG**, Hur J, Choi EY, Hong KS, Lee W, Ahn JH. Prognostic Factors for Severe Coronavirus Disease 2019 in Daegu, Korea. *J Korean Med Sci* 2020; **35**: e209 [PMID: 32537954 DOI: 10.3346/jkms.2020.35.e209]

21 **Pan F**, Yang L, Li Y, Liang B, Li L, Ye T, Li L, Liu D, Gui S, Hu Y, Zheng C. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. *Int J Med Sci* 2020; **17**: 1281-1292 [PMID: 32547323 DOI: 10.7150/ijms.46614]

22 **Feng X**, Li S, Sun Q, Zhu J, Chen B, Xiong M, Cao G. Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis. *Front Med (Lausanne)* 2020; **7**: 301 [PMID: 32582743 DOI: 10.3389/fmed.2020.00301]

23 **Lin Z**, Long F, Yang Y, Chen X, Xu L, Yang M. Serum ferritin as an independent risk factor for severity in COVID-19 patients. *J Infect* 2020; **81**: 647-679 [PMID: 32592705 DOI: 10.1016/j.jinf.2020.06.053]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Medical Ethics Committee of Fujian Medical University Union Hospital Institutional Review Board (No. 2020KJTXGF001).

**Informed consent statement:** Patients signed an informed consent.

**Conflict-of-interest statement:** The authors have no conflicts of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 17, 2021

**First decision:** November 3, 2021

**Article in press:** December 2, 2021

**Specialty type:** Respiratory system

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Valencia GA **S-Editor:** Wang JL **L-Editor:** A **P-Editor:** Wang JL

**Figure Legends**

**Table 1 Patient Demographic Characteristics**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Indicator** | | **Control group (*n* = 32)** | **Glucocorticoid group (*n* = 38)** | **summatio*n*** | **χ2 or Hc value** | ***P* value** |
| Gender | F | 15 | 15 | 30 | 0.389 | 0.533 |
| M | 17 | 23 | 40 |
| Underlying diseases | N | 18 | 23 | 41 | 0.131 | 0.717 |
| Y | 14 | 15 | 29 |
| Hypertension | N | 24 | 30 | 54 | 0.154 | 0.695 |
| Y | 8 | 8 | 16 |
| Type 2 diabetes | N | 28 | 31 | 59 | 0.460 | 0.498 |
| Y | 4 | 7 | 11 |
| Classification | Common type | 20 | 22 | 42 | 0.154 | 0.695 |
| Severe type | 12 | 16 | 28 |
| Fever | N | 8 | 4 | 12 | 2.562 | 0.109 |
| Y | 24 | 34 | 58 |
| Cough | N | 11 | 13 | 24 | 0 | 0.988 |
| Y | 21 | 25 | 46 |
| Polypnea | N | 28 | 26 | 54 | 3.586 | 0.058 |
| Y | 4 | 12 | 16 |
| Fatigue | N | 22 | 30 | 52 | 0.946 | 0.331 |
| Y | 10 | 8 | 18 |
| Muscle soreness | N | 25 | 36 | 61 | 2.924 | 0.087 |
| Y | 7 | 2 | 9 |
| Poor appetite | N | 30 | 34 | 64 | 0.043 | 0.835 |
| Y | 2 | 4 | 6 |
| Chest distress | N | 29 | 38 | 67 | 1.787 | 0.181 |
| Y | 3 | 0 | 3 |
| Chest pain | N | 31 | 37 | 68 |  | 1 |
| Y | 1 | 1 | 2 |
| Diarrhea | N | 31 | 37 | 68 |  | 1 |
| Y | 1 | 1 | 2 |
| [Throatpain](javascript:;) | N | 31 | 38 | 69 |  | 0.457 |
| Y | 1 | 0 | 1 |

F: Female; M: Male.

**Table 2 Comparison of age, the time of medication in the two groups (mean ± SD)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Indicator** | **Control group** | **Corticosteroid group** | ***t* value** | ***P* value** |
| Age (yr) | 62.84 ± 13.97 | 59.05 ± 13.95 | 1.132 | 0.262 |
| The time of medication (d) | 7.66 ± 2.29 | 6.82 ± 1.84 | 1.668 | 0.101 |

**Table 3 The relationship between duration, dose of methylprednisolone uses and CT improvement in the corticosteroid group (mean ± SD)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Indicator** | **Non-obvious absorption group (*n* = 4)** | **Obvious absorption group (*n* = 34)** | ***t* value** | ***P* value** |
| Duration of methylprednisolone use (d) | 6.0 ± 2.0 | 6.44 ± 1.86 | -0.445 | 0.659 |
| Total methylprednisolone dose (mg) | 210.0 ± 66.33 | 239.15 ± 86.09 | -0.652 | 0.519 |
| Daily methylprednisolone dose (mg) | 35.72 ± 4.95 | 38.55 ± 13.17 | -0.422 | 0.676 |

**Table 4 The results of SARS-CoV-2 RNA and chest CT absorbtion**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Indicator** | | **Control group** | **Corticosteroid group** | **Summation** | **χ2 or Hc value** | ***P*-value** |
| SARS-CoV-2 RNA before medication | N | 21 | 28 | 49 | 0.537 | 0.464a |
| P | 11 | 10 | 21 |
| SARS-CoV-2 RNA after medication | N | 30 | 37 | 67 | 0.023 | 0.879a |
| P | 2 | 1 | 3 |
| CT absorption degree after medication | No absorption | 13 | 0 | 13 | 41.681 | < 0.001b |
| Slightly absorption | 15 | 4 | 19 |
| Obvious absorption | 4 | 34 | 38 |

aThere was no statistically difference in the negative conversion rate of SARS-CoV-2 nucleic acid between the two groups.

bThere was significant difference in CT absorption degree between the two groups.

N: Negtive; P: Positive; CT: Computerized tomography; No absorption: No change in inflammatory range; Slightly absorption: The range of inflammation is absorbed than before, less than 25%; Obvious absorption: The range of inflammation is absorbed than before, more than 25%.

**Table 5 Comparison of the total clearance time of SARS-CoV-2 nucleic acid in the two groups (mean ± SD)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Indicator** | **Control group** | **Corticosteroid group** | ***t* value** | ***P* value** |
| The total clearance time (d) | 22.13 ± 7.66 | 20.89 ± 7.70 | 0.667 | 0.507 |

**Table 6 Comparison of laboratory results between the two groups before and after the medication (mean ± SD)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Indicator** | **Group** | **Before the medication** | **After the medication** |
| [Lymphocyte](javascript:;) | Control group | 1.35 ± 0.39 | 1.58 ± 0.44 |
| Corticosteroid group | 1.34 ± 0.54 | 1.61 ± 0.62 |
| ESR | Control group | 25.22 ± 18.41 | 15.41 ± 9.67 |
| Corticosteroid group | 25.71 ± 14.74 | 13.79 ± 8.24 |
| LDH | Control group | 171.66 ± 50.70 | 136.06 ± 36.80 |
| Corticosteroid group | 226.13 ± 82.36 | 187.05 ± 68.53 |
| SF | Control group | 344.69 ± 209.42 | 202.22 ± 109.76 |
| Corticosteroid group | 428.28 ± 249.29 | 255.19 ± 105.59 |

ESR: [Erythrocyte](javascript:;) [sedimentation](javascript:;) [rate](javascript:;); LDH: Lactate [dehydrogenase](javascript:;); SF: [Serum](javascript:;) [ferritin](javascript:;).

**Table 7 Comparison of laboratory results between the two groups before and after the medication (median)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Indicator** | **group** | **Before medication** | **After medication** |
| hs-CRP | Control group | 2.38 (1.12-10.96) | 1.57 (1.33-3.20) |
| Corticosteroid group | 5.65 (1.57-22.0) | 2.75 (0.87-9.0) |
| IL-6 | Control group | 8.29 (6.81-11.14) | 6.60 (5.64-8.38) |
| Corticosteroid group | 10.30 (7.78-13.08) | 8.21 (6.26-9.79) |
| CK-MB | Control group | 0.60 (0.40-1.15) | 0.60 (0.40-0.90) |
| Corticosteroid group | 6.0 (0.90-8.80) | 4.25 (0.80-6.90) |
| D-dimer | Control group | 0.80 (0.40-1.05) | 0.54 (0.20-0.80) |
| Corticosteroid group | 1.14 (0.85-1.89) | 0.89 (0.57-1.08) |

hs-CRP: Hypersensitive C-reactive protein; IL-6: Interleukin-6; CK-MB: Creatine kinase-MB.

**Table 8 Comparison of different indicators between the two groups by repeated-measures analysis**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Indicator** | **Group** | | **Time** | | **Group × Time** | |
| ***F* value** | ***P* value** | ***F* value** | ***P* value** | ***F* value** | ***P* value** |
| [Lymphocyte](javascript:;) | 0.013 | 0.909 | 21.331 | < 0.001 | 0.203 | 0.654 |
| ESR | 0.038 | 0.846 | 66.617 | < 0.001 | 0.627 | 0.431 |
| LDH | 13.725 | < 0.001 | 48.610 | < 0.001 | 0.106 | 0.746 |
| SF | 3.152 | 0.080 | 61.862 | < 0.001 | 0.582 | 0.448 |

ESR: [Erythrocyte](javascript:;) [sedimentation](javascript:;) [rate](javascript:;); LDH: Lactate [dehydrogenase](javascript:;); SF: [Serum](javascript:;) [ferritin](javascript:;).

**Table 9 Comparison of different indicators between the two groups by using generalized linear mixed model**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Indicator** | **Group** | | **Time** | | **Group × Time** | |
| ***F* value** | ***P* value** | ***F* value** | ***P* value** | ***F* value** | ***P* value** |
| hs-CRP | 2.376 | 0.128 | 5.237 | 0.025 | 0.005 | 0.945 |
| IL6 | 0.022 | 0.882 | 13.798 | < 0.001 | 0.787 | 0.378 |
| CK-MB | 29.785 | < 0.001 | 10.998 | 0.001 | 1.429 | 0.236 |
| D-dimer | 11.266 | 0.001 | 18.322 | < 0.001 | 2.926 | 0.092 |

hs-CRP: Hypersensitive C-reactive protein; IL-6: Interleukin-6; CK-MB: Creatine kinase-MB.

**Table 10 The adverse reaction of corticosteroids**

|  |  |  |
| --- | --- | --- |
|  | **Control group, *n* = 32 (%)** | **Corticosteroid group, *n* = 38 (%)** |
| Gastrointestinal bleeding | 0 | 0 |
| Secondary infection | 0 | 0 |
| Mental disorders | 0 | 0 |
| Elevated blood glucose | 0 (0%) | 11 (28.95%) |
| Diabetic ketoacidosis | 0 | 0 |
| Hypertension | 0 | 0 |
| Sever electrolyte disorders | 0 | 0 |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**